EnVivo Pharmaceuticals announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.

Patients, discharged from hospitals on ventilator support and with cognitive impairments, fare poorly four months later. Researchers from the Frances Payne Bolton School of Nursing at Case Western Reserve University report these findings in American Journal of Critical Care.

A condition that affects the memory and concentration of cancer patients undergoing chemotherapy is sustained in a subgroup of patients, compromising their ability to function and long-term quality of life, according to research presented on wednesday at a major cancer conference.

Beth Israel Deaconess Medical Center (BIDMC) neurologists Alvaro Pascual-Leone, MD, PhD, and Daniel Tarsy, MD, have been awarded grants totaling more than $1.5 million from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to conduct investigations aimed at improving the quality of life for patients with Parkinson’s disease.

Marijuana is the most widely used illicit drug by adolescents, with almost 42% of high school seniors admitting to having experimented with it. Continued marijuana use may result in a number of serious consequences including depression, cognitive impairment, cardiovascular disease, and certain forms of cancer. As such, it is critical to prevent marijuana use by [...]